CMMB double bottom supply line test might end up in a breakoutIf it can hold the double bottom, it can play out the divergence and push upwards.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.14 USD
−24.16 M USD
0.00 USD
12.62 M
About Chemomab Therapeutics Ltd.
Sector
Industry
CEO
Adi Mor
Website
Headquarters
Tel Aviv
Founded
2011
FIGI
BBG00N0PMGK1
Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. It discovers and develops therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.
CMMBChemomab Therapeutics Ltd (NASDAQ:CMMB) My opinion remains intact about this small bio cap. I will not sell a single share below $40 unless something bad happens, but that does not seem to be the case according to the recent news and reports. The stock has been falling on very low volume. The compan
CMMBChemomab Therapeutics Ltd (NASDAQ:CMMB) With Friday’s breakout movement above 18 on decent volume, the downtrend is over. A break higher above the recent highs 19.35 would help the stock move to the $22.75-$24 area. Momentum indicators are turning up, a positive sign.
CMMBChemomab Therapeutics Ltd (NASDAQ:CMMB) My long position on this small bio play remains intact. On the technical side, the stock has been pulling back on low volume to test the breakout zone around the $20 area. If this zone is respected next week, I expect that the next rebound will push the price
CMMBI think Chemomab Therapeutics Ltd (NASDAQ:CMMB) is building a nice base for take off. Some technical indicators are showing positive divergences on a daily basis. We could be in the early stages of a nice rally for this stock. Keep a close eye on it going forward. The stock currently trades at just
Short Squeeze - CMMBIdea for Chemomab Therapeutics Ltd.:
- 131% borrow fee for shares. 47 shares available for borrow, according to iborrowdesk.
- Bottom of Risk Range:
- S3 Filing Sales Agreement with Cantor Fitzgerald & Co. dated Apr 30, 2021. fintel.io
- Cantor Fitzgerald assigned overweight rating on CMMB and r
CMMBI've mentioned Chemomab Therapeutics Ltd (NASDAQ:CMMB) for the bulls out there. On Friday, Oppenheimer initiated coverage on the stock with an Outperform rating and announced a price target of $42 per share. It seems that analysts are also seeing what I'm seeing, a stock trading at bargain prices wi
CMMBChemomab Therapeutics Ltd (NASDAQ:CMMB) This is a stock that I like a lot for another big rally. In the last couple of times it went under $30, the stock had a big spike right after. Don't worry with the SEC Form S-3 filed on Friday, for me means news ahead, before the raise ;) read the market behin
Anchiano and Chemomab merge, 16:1 reverse split$CMMB = New $ANCN
Chemomab just merged with Anchiano
There was a 16:1 reverse split on ANCN shares last nigth as part of the merger
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.